Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 16, 2026
Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysisRonald Chow, Daniel Zhang, Gregory W Chai, et al.Journal of Cancer|April 14, 2023
Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective StudyIzumi Nasu, Masahiro Kondo, Ryuji Uozumi, et al.Biological & Pharmaceutical Bulletin|July 30, 2026
Preventive Effects of Non-sedating and Sedating Histamine H1 Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational StudyMayu Yakumaru-Suzukawa, Tohru Aomori, Norifumi Suzuki, et al.International Journal of Clinical Oncology|April 16, 2026
Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study TeamYohei Iimura, Junichi Higuchi, Akimitsu Maeda, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 13, 2025
Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 studyHironori Fujii, Masami Tsuchiya, Daichi Watanabe, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 17, 2024
The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational studyHironori Fujii, Masami Tsuchiya, Daichi Watanabe, et al.International Journal of Clinical Oncology|May 16, 2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesisHirotoshi Iihara, Masakazu Abe, Makoto Wada, et al.International Journal of Clinical Oncology|July 21, 2026
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasoneTakeshi Aoyama, Hirotoshi Iihara, Masakazu Abe, et al.International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.Pageof 12